Tenon Medical (TNON) 10-Q10 Nov 222022 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2022	Nov. 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Entity File Number	001-41364
Entity Registrant Name	TENON MEDICAL, INC.
Entity Central Index Key	0001560293
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-5574718
Entity Address, Address Line One	104 Cooper Court
Entity Address, City or Town	Los Gatos
Entity Address, Country	CA
Entity Address, Postal Zip Code	95032
City Area Code	408
Local Phone Number	649-5760
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	TNON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,236,801

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 3,153	$ 2,917
Short-term investments	9,381	4,404
Accounts receivable	144	76
Inventory	810	188
Prepaid expenses	177	87
Total current assets	13,665	7,672
Fixed assets - net	294	101
Deposits	51	41
Operating lease right-of-use asset	927	1,084
Deferred offering costs	0	374
TOTAL ASSETS	14,937	9,272
Current liabilities:
Accounts payable	422	478
Accrued expenses	603	1,088
Current portion of operating lease liability	241	202
Convertible notes payable and accrued interest, net of debt discount of $0 and $31 at June 30, 2022 and December 31, 2021, respectively	0	12,857
Convertible notes payable and accrued interest due to related parties, net of debt discount of $0 and $2 at June 30, 2022 and December 31, 2021, respectively	0	649
Total current liabilities	1,266	15,274
Operating lease liability, net of current portion	724	911
Total liabilities	1,990	16,185
Commitments and contingencies (Notes 6 and 9)
Stockholders' equity (deficit):
Common stock, $0.001 par value; 130,000,000 and 10,487,904 shares authorized at September 30, 2022 and December 31, 2021, respectively; 11,236,801 and 989,954 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	11	1
Additional paid-in capital	44,691	113
Accumulated deficit	(31,587)	(20,575)
Accumulated other comprehensive income (loss)	(168)	(91)
Total stockholders' equity (deficit)	12,947	(20,552)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT)	14,937	9,272
Series A Convertible Preferred Stock [Member]
Convertible preferred stock
Convertible Preferred Stock	0	12,367
Series B Convertible Preferred Stock [Member]
Convertible preferred stock
Convertible Preferred Stock	$ 0	$ 1,272

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt discount	$ 0	$ 31
Debt discount related to related parties	$ 0	$ 2
Common stock par or stated value per share	$ 0.001	$ 0.001
Common stock shares authorized	130,000,000	10,487,904
Common stock shares issued	11,236,801	989,954
Common stock shares outstanding	11,236,801	989,954
Series A Convertible Preferred Stock [Member]
Temporary equity par or stated value per share	$ 0.001	$ 0.001
Temporary equity shares authorized	4,500,000	2,805,839
Temporary equity shares issued	0	2,550,763
Temporary equity shares outstanding	0	2,550,763
Series B Convertible Preferred Stock [Member]
Temporary equity par or stated value per share	$ 0.001	$ 0.001
Temporary equity shares authorized	491,222	491,222
Temporary equity shares issued	0	491,222
Temporary equity shares outstanding	0	491,222

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 208	$ 70	$ 414	$ 107
Cost of sales	302	18	848	38
Gross (Loss) Profit	(94)	52	(434)	69
Operating Expenses
Research and development	797	601	2,016	925
Sales and marketing	645	556	2,864	1,473
General and administrative	1,726	992	5,483	1,570
Total Operating Expenses	3,168	2,149	10,363	3,968
Loss from Operations	(3,262)	(2,097)	(10,797)	(3,899)
Other Income (Expense)
Gain on investments	72	1	108	1
Interest expense	0	(267)	(362)	(340)
Other income (expense)	19	0	39	(1)
Total Other Income (Expense), net	91	(266)	(215)	(340)
Net Loss	(3,171)	(2,363)	(11,012)	(4,239)
Loss attributable to non-controlling interest		(22)	0	(33)
Net Loss Attributable to Tenon Medical, Inc.	$ (3,171)	$ (2,341)	$ (11,012)	$ (4,206)
Net Loss Attributable to Tenon Medical, Inc. Per Share of Common Stock
Basic	$ (0.28)	$ (2.55)	$ (1.59)	$ (4.85)
Diluted	$ (0.28)	$ (2.55)	$ (1.59)	$ (4.85)
Weighted-Average Shares of Common Stock Outstanding
Basic	11,237	919	6,920	868
Diluted	11,237	919	6,920	868
Statement of Comprehensive Income [Abstract]
Net loss	$ (3,171)	$ (2,363)	$ (11,012)	$ (4,239)
Unrealized loss on investments	(10)	0	(37)	0
Foreign currency translation adjustment	(19)	1	(40)	1
Total Comprehensive Loss	(3,200)	(2,362)	(11,089)	(4,238)
Comprehensive loss attributable to non-controlling interest	0	(22)	0	(33)
Total comprehensive loss attributable to Tenon Medical, Inc.	$ (3,200)	$ (2,340)	$ (11,089)	$ (4,205)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Noncontrolling Interest [Member]	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member] Common Stock [Member]	Series A Convertible Preferred Stock [Member] Additional Paid-in Capital [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member] Common Stock [Member]	Series B Convertible Preferred Stock [Member] Additional Paid-in Capital [Member]
Beginning Balance at Dec. 31, 2020							$ 0			$ 1,272
Beginning Balance (in shares) at Dec. 31, 2020							0			491,222
Beginning Balance at Dec. 31, 2020	$ (2,709)	$ 1	$ 126	$ (4,486)	$ (57)	$ 1,707
Beginning Balance (in shares) at Dec. 31, 2020		830,000
Stock-based compensation expense	208		208
Common stock issued for services	816		816
Common stock issued for services, Share		115,507
Other comprehensive income	1				1
Net loss	(4,239)			(4,206)		(33)
Ending Balance at Sep. 30, 2021							$ 0			$ 1,272
Ending Balance (in shares) at Sep. 30, 2021							0			491,222
Ending Balance at Sep. 30, 2021	(5,923)	$ 1	1,150	(8,692)	(56)	1,674
Ending Balance (in shares) at Sep. 30, 2021		945,507
Beginning Balance at Jun. 30, 2021							$ 0			$ 1,272
Beginning Balance (in shares) at Jun. 30, 2021							0			491,222
Beginning Balance at Jun. 30, 2021	(4,140)	$ 1	571	(6,351)	(57)	1,696
Beginning Balance (in shares) at Jun. 30, 2021		883,757
Stock-based compensation expense	143		143
Common stock issued upon conversion							$ 436	$ 0	$ 436
Common stock issued upon conversion, Share								61,750
Common stock issued upon conversion of debt							$ 0
Common stock issued upon conversion of debt, Share							0
Other comprehensive income	1				1
Net loss	(2,363)			(2,341)		(22)
Ending Balance at Sep. 30, 2021							$ 0			$ 1,272
Ending Balance (in shares) at Sep. 30, 2021							0			491,222
Ending Balance at Sep. 30, 2021	(5,923)	$ 1	1,150	(8,692)	(56)	1,674
Ending Balance (in shares) at Sep. 30, 2021		945,507
Beginning Balance at Dec. 31, 2021							$ 12,367			$ 1,272
Beginning Balance (in shares) at Dec. 31, 2021							2,550,763			491,222
Beginning Balance at Dec. 31, 2021	(20,552)	$ 1	113	(20,575)	(91)	0
Beginning Balance (in shares) at Dec. 31, 2021		989,954
Stock-based compensation expense	1,755		1,755
Issuance of common stock and warrants, net of issuance costs	13,765	$ 3	13,762
Issuance of common stock and warrants, net of issuance costs, Share		3,200,000
Common stock issued upon conversion							$ 12,367	$ 2	$ 12,365	$ 1,272		$ 1,272
Common stock issued upon conversion, Share								2,447,728			245,614
Common stock issued upon conversion of debt							$ (12,367)			$ (1,272)
Common stock issued upon conversion of debt, Share							(2,550,763)			(491,222)
Common stock issued upon conversion of debt	13,868	$ 4	13,864
Common stock issued upon conversion of debt, Share		3,955,415
Common stock issued for services	1,561	$ 1	1,560
Common stock issued for services, Share		398,090
Other comprehensive income	(77)				(77)
Net loss	(11,012)			(11,012)
Ending Balance at Sep. 30, 2022							$ 0			$ 0
Ending Balance (in shares) at Sep. 30, 2022							0			0
Ending Balance at Sep. 30, 2022	12,947	$ 11	44,691	(31,587)	(168)	0
Ending Balance (in shares) at Sep. 30, 2022		11,236,801
Beginning Balance at Jun. 30, 2022							$ 0			$ 0
Beginning Balance (in shares) at Jun. 30, 2022							0			0
Beginning Balance at Jun. 30, 2022	15,113	$ 11	43,657	(28,416)	(139)	0
Beginning Balance (in shares) at Jun. 30, 2022		11,236,801
Stock-based compensation expense	1,034		1,034
Other comprehensive income	(29)				(29)
Net loss	(3,171)			(3,171)
Ending Balance at Sep. 30, 2022							$ 0			$ 0
Ending Balance (in shares) at Sep. 30, 2022							0			0
Ending Balance at Sep. 30, 2022	$ 12,947	$ 11	$ 44,691	$ (31,587)	$ (168)	$ 0
Ending Balance (in shares) at Sep. 30, 2022		11,236,801

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows from Operating Activities
Net loss	$ (11,012)	$ (4,239)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss on investments	(37)	(1)
Non-cash interest expense	362	340
Stock-based compensation expense	1,755	208
Common stock issued for services	1,561	816
Depreciation and amortization	53	1
Amortization of operating right-of-use asset	157	62
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(68)	(56)
Inventory	(622)	21
Prepaid expenses and other assets	(100)	(129)
Accounts payable	(56)	242
Accrued expenses	(485)	168
Operating lease liability	(148)	(35)
Net cash used in operating activities	(8,640)	(2,602)
Cash Flows from Investing Activities
Sales of short-term investments	4,404	0
Purchases of short-term investments	(9,381)	(7,861)
Purchases of property and equipment	(246)	(18)
Net cash used in investing activities	(5,223)	(7,879)
Cash Flows from Financing Activities
Proceeds from issuance of common stock, net of issuance costs	14,139	0
Proceeds from issuance of convertible notes payable	0	12,072
Repayment of notes payable	0	(131)
Debt issuance costs	0	(71)
Deferred offering costs	0	(222)
Net cash provided by financing activities	14,139	11,648
Effect of foreign currency translation on cash flow	(40)	(4)
Net Increase in Cash and Cash Equivalents	236	1,163
Cash and Cash Equivalents at Beginning of Period	2,917	245
Cash and Cash Equivalents at End of Period	3,153	1,409
Supplemental Disclosures of Cash Flow Information
Interest	0	1
Income taxes	0	1
Non-cash investment and financing activities:
Common stock issued upon conversion of preferred stock	13,639	0
Common stock issued upon conversion of debt	13,868	0
Right-of-use assets obtained in exchange for lease liability	0	1,195
Conversion of trade payable to law firm to note payable	$ 0	$ 556

Organization and Business

Organization and Business	9 Months Ended
Organization and Business	Sep. 30, 2022
Organization And Business Disclosure [Abstract]
Organization and Business	1. Organization and Business Nature of operations Tenon Medical, Inc. (the “Company”), was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed a novel, less invasive, inferior-posterior approach to the sacroiliac joint using a single, robust, titanium implant for treatment of the most common types of sacroiliac joint (the “SI Joint”) disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for its primary product, The Catamaran TM Basis of consolidation The consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Tenon Technology AG (“TTAG”), a Swiss company. TTAG was a majority-owned subsidiary until October 28, 2021, at which date the Company acquired the remaining non-controlling interest of TTAG (see Note 8). All intercompany balances and transactions have been eliminated in consolidation.

Summary of Significant Accounti

Summary of Significant Accounting Principles	9 Months Ended
Summary of Significant Accounting Principles	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Principles	2. Summary of Significant Accounting Principles Basis of presentation We have prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the SEC. As permitted under these rules and regulations, we have condensed or omitted certain financial information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These condensed consolidated financial statements have been prepared on the same basis as our annual consolidated financial statements and, in management’s opinion, reflect all adjustments consisting only of normal recurring adjustments that are necessary for a fair presentation of our financial information. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. The financial statements of the subsidiary are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects. The amount of consolidated net loss attributable to the Company and ownership interests in TTAG held by parties other than the Company are both presented on the face of the Consolidated Statements of Operations. As TTAG is a wholly-owned subsidiary as of September 30, 2022, this separate presentation has been discontinued for the three and nine months then ended. Further, as the Company purchased the non-controlling interest in TTAG as of October 28, 2021, the amount of consolidated net loss attributable to the Company and the non-controlling interest are both presented on the face of the Consolidated Statements of Operations and Comprehensive Loss. These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in our amended Registration Statement. The Company’s significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in our amended Registration Statement. There have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2022. Going concern uncertainty and liquidity requirements The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and starts the commercial launch of The Catamaran System. On April 29, 2022, the Company closed an initial public offering (the “IPO”) of its common stock for proceeds of $13,765, net of issuance costs. Based on the Company’s current level of revenues and expenditures, the Company believes that its existing cash and cash equivalents and short-term investments as of September 30, 2022 will Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, obsolescence of inventory, stock-based compensation and the fair value of the Company’s common stock and preferred stock. Income Taxes The Company accounts for income taxes utilizing ASC 740, “Income Taxes”. ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company’s financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Impact of COVID-19 In March 2020, the World Health Organization declared the coronavirus (“COVID-19”) outbreak to be a pandemic. During the years ended December 31, 2021 and 2020 and the nine months ended September 30, 2022, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these consolidated financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it. Net loss per share Basic net loss per share is based upon the weighted-average number of common shares outstanding. Diluted net loss per share is based on the assumption that all potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. The Company’s weighted-average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive. The Company had the following dilutive common stock equivalents as of September 30, 2022 and 2021 which were excluded from the calculation because their effect was anti-dilutive. September 30, September 30, Outstanding restricted stock units 1,318,530 — Outstanding stock options 841,344 705,394 Outstanding warrants 121,000 25,000 Common shares convertible from notes payable — 2,079,510 Common shares convertible from preferred stock — 245,611 Total 2,280,874 3,055,515 Recent Accounting Pronouncements There have been no accounting pronouncements or changes in accounting pronouncements in the nine months ended September 30, 2022 that are significant or potentially significant to the Company.

Investments

Investments	9 Months Ended
Investments	Sep. 30, 2022
Investments [Abstract]
Investments	3. Investments The following table sets forth by level, within the fair value hierarchy, the Company’s investments at fair value as of September 30, 2022 and December 31, 2021: Level 2 Corporate debt securities: September 30, 2022 $ 9,381 December 31, 2021 $ 4,404 Cost and fair value of available-for-sale investments as of September 30, 2022 and December 31, 2021 are as follows: Amortized Gross Gross Fair Corporate debt securities: September 30, 2022 $ 9,418 $ — $ (37 ) $ 9,381 December 31, 2021 $ 4,404 $ — $ — $ 4,404 All of the investments with gross unrealized losses have been in a continuous loss position for less than 12 months. During the three and nine months ended September 30, 2022 and 2021, the Company did not recognize any significant other-than-temporary impairment losses because the Company does not intend to sell the investments before recovery of their amortized cost bases. During the three and nine months ended September 30, 2022, there were net gains of approximately $72 and $108, respectively, included in the Company’s net loss. During the three and nine months ended September 30, 2021, there were no such gains included in the Company’s net loss. Accrued interest as of September 30, 2022 and December 31, 2021 was approximately $6 and $18, respectively, and is included in prepaid expenses in the Company’s consolidated balance sheet.

Fixed Assets

Fixed Assets	9 Months Ended
Fixed Assets	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Fixed Assets	4. Fixed Assets Fixed assets, net, consisted of the following: September 30, 2022 December 31,2021 Catamaran Tray Sets $ 270 $ 77 IT Equipment 56 17 Lab Equipment 14 — Office Furniture 9 9 Fixed assets, gross 349 103 Less: accumulated depreciation (55 ) (2 ) Fixed assets, net $ 294 $ 101 Depreciation expense was approximately $24 and $1 for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was approximately $53 and $1 for the nine months ended September 30, 2022 and 2021, respectively.

Accrued Expenses

Accrued Expenses	9 Months Ended
Accrued Expenses	Sep. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consisted of the following: September 30, December 31, Accrued compensation $ 339 $ 846 Accrued commissions 49 14 Other accrued expenses 215 228 Total accrued expenses $ 603 $ 1,088

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	6. Debt Convertible notes payable – parent company During 2015, the Company issued a $53 convertible promissory note to a consultant that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 90% of the price per share paid by the other cash purchasers in the future financing. In June 2019, the note and its accrued interest to date was replaced by a $68 convertible promissory note that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $1,000, at a conversion price equal to 90% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of June 12, 2021. In May 2021, the note was again replaced by a $68 convertible promissory note with a maturity date of May 7, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 80% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $14, respectively. During 2016, the Company issued a $118 convertible promissory note to a vendor that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 90% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of January 1, 2019 and remained unpaid during 2019 and 2020. In April 2021, the note was replaced by a $118 convertible promissory note with a maturity date of April 30, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 80% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $56, respectively. In October 2019, the Company issued a $70 convertible promissory note to the Company’s former Chief Executive Officer that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 80% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of October 12, 2022. In April 2021, the note was replaced by a $70 convertible promissory note with a maturity date of April 30, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $12, respectively. In October 2019, the Company issued a $50 convertible promissory note to an investor that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 80% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of October 21, 2022. In May 2021, the note was replaced by a $50 convertible promissory note with a maturity date of May 3, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $9, respectively. In November 2020, the Company issued a $200 convertible promissory note to the same investor that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $2,000, at a conversion price equal to 80% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of November 16, 2022. In May 2021, the note was replaced by a $200 convertible promissory note with a maturity date of May 3, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or 70% of the price per share paid by the other cash purchasers in the future financing. Accrued interest at September 30, 2022 and December 31, 2021 was approximately $0 and $18, respectively. In January 2021, the Company issued a promissory note of $131 to a law firm. The note bore interest at 3.0% per annum and had a maturity date of the earlier of July 27, 2021, the closing of a debt or equity financing, or the closing of a change in control transaction. The interest rate was to increase to 5.0% if all principal and interest had not been paid by the maturity date. The Company repaid this note and accrued interest in May 2021. In April 2021, the Company issued two convertible promissory notes of $40 and $170 to the vendor described in the second paragraph above that, along with accrued interest at an annual rate of 8.0%, were automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or 70% of the price per share paid by the other cash purchasers in the future financing. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $11, respectively. From May through July 2021, in multiple rounds of closings the Company issued convertible promissory notes to multiple investors for aggregate proceeds of approximately $12,177, with maturity dates twelve months from the issuance dates. Of this amount, $620 of notes were issued to related officers, directors, and their family members, and a $50 note was issued to the Chief Executive Officer of the Representative described in Note 9. The notes, along with accrued interest at an annual rate of 8.0%, were automatically convertible upon an IPO, a capital stock financing of at least $5,000, or a change of control transaction. The conversion price upon an IPO or a capital stock financing was equal to the lesser of 70% of the price per share paid by the other cash purchasers, or the price per share at a Company valuation of $22,500. The Company recorded debt issuance costs of approximately $71 as a discount on the convertible notes payable balance. Accrued interest at September 30, 2022 and December 31, 2021 was approximately $0 and $527, respectively. On April 29, 2022, as a result of the completion of the IPO and as required under the terms of the convertible notes payable described above, the Company converted the entirety of the outstanding principal and accrued interest of the outstanding convertible notes payable to 3,955,415 shares of the Company’s common stock at the conversion price detailed above and issued the common stock to the noteholders, fully satisfying the Company’s obligations. Convertible notes payable – subsidiary In June 2021, the Company’s subsidiary issued a convertible promissory note for approximately $107 to TTAG’s minority shareholder. This note, along with accrued interest at an annual rate of 8.0%, could be applied to future TTAG capital increases. The Company purchased this note and accrued interest of approximately $114 in October 2021 from TTAG’s minority shareholder.

Leases

Leases	9 Months Ended
Leases	Sep. 30, 2022
Leases [Abstract]
Leases	7. Leases In June 2021, the Company entered into a facility lease agreement for its company headquarters in Los Gatos, California. This non-cancelable operating lease expires in June 2026. The Company includes options that are reasonably certain to be exercised as part of the determination of lease terms. The Company may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within operating leases. In addition to base rent payments, leases may require the Company to pay directly for taxes and other non-lease components, such as insurance, maintenance, and other operating expenses, which may be dependent on usage or vary month-to-month. Non-lease components were considered and determined not to be material. The Company determined if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and performed the lease classification test as of the lease commencement date. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease’s commencement date based on the present value of lease payments over the lease term. When a lease did not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Operating lease costs for the facility lease were $73 and $73 for the three months ended September 30, 2022 and 2021, respectively, and $219 and $85 for the nine months ended September 30, 2022 and 2021, respectively. Lease costs are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Supplemental balance sheet information related to leases was as follows: September 30, December 31, 2022 2021 Operating lease right-of-use assets $ 927 $ 1,084 Operating lease liability, current $ (241 ) $ (202 ) Operating lease liability, noncurrent (724 ) (911 ) Total operating lease liabilities $ (965 ) $ (1,113 ) Future maturities of operating lease liabilities as of September 30, 2022 were as follows: 2022 $ 73 2023 293 2024 301 2025 310 2026 144 Total lease payments 1,121 Less: imputed interest (156 ) Present value of operating lease liabilities $ 965 Other information: Cash paid for operating leases for the nine months ended September 30, 2022 $ 212 Cash paid for operating leases for the nine months ended September 30, 2021 $ 58 Remaining lease term - operating leases (in years) 3.75 Average discount rate - operating leases 8.0 %

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2022
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity The Amended and Restated Certificate of Incorporation dated February 18, 2014 authorized the issuance of 3,937,550 shares of common stock and 2,099,525 shares of preferred stock, with a par value of $0.001 per share. In In In Reverse Stock Split On April 6, 2022, the Company effected a 1:2 reverse stock split (the “Reverse Stock Split”) by filing an amendment to the Company’s Amended and Restated Certificate Incorporation, as amended, with the Delaware Secretary of State. The Reverse Stock Split combined every two shares of our common stock issued and outstanding immediately prior to effecting the Reverse Stock Split into one share of common stock. Similarly, shares of Series A and Series B Preferred Stock became convertible into common stock at a conversion rate of one-to-0.5, subject to adjustments for stock dividends, splits, combinations, and similar events. No fractional shares were issued in connection with the Reverse Stock Split. All historical and per share amounts reflected throughout this document have been adjusted to reflect the Reverse Stock Split. The authorized number of shares and the par value per share of the Company’s common stock were not affected by the Reverse Stock Split. Initial Public Offering On April 26, 2022, the Company’s Registration Statement relating to the IPO was declared effective by the SEC. The IPO consisted of 3,200,000 shares of common stock, par value $0.001 per share at a public offering price of $5.00 per share. Pursuant to the Underwriting Agreement dated April 26, 2022, between the Company, The Benchmark Company, LLC (“Benchmark”) and Valuable Capital Limited (together with Benchmark, the “Underwriters”), the Company granted the Underwriters warrants to purchase a total of 96,000 shares of the Company’s common stock at an exercise price of $5.00 per share. The warrants expire on the fifth anniversary of the commencement of sales under the IPO. On April 27, 2022, the shares of the Company’s common stock began trading on the Nasdaq Capital Market LLC under the symbol “TNON.” On April 29, 2022, the IPO closed, and the Company received approximately $13.8 million in net proceeds from the IPO after deducting the underwriting discount and commission and other estimated IPO expenses payable by the Company. As a result of the completion of the IPO and as required under the terms of the convertible notes payable described in Note 6, the Company converted the entirety of the related outstanding principal and accrued interest to 3,955,415 shares of the Company’s common stock at the conversion price detailed in Note 6 and issued the common stock to the noteholders, fully satisfying the Company’s obligations. On April 29, 2022, as result of the completion of the IPO, the Company converted all shares of Series A and Series B Preferred Stock to 2,693,342 shares of the Company’s common stock at the conversion rate detailed below and issued the common stock to the preferred stockholders, fully satisfying the Company’s obligations. This includes 1,172,346 shares issued to TTAG’s minority shareholder in accordance with the anti-dilution protection provisions of the Exchange Agreement. Concurrent with the completion of the IPO and in accordance with the Amended and Restated Exclusive Sales Representative Agreement executed in May 2021, the counterparty to the agreement received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering and was issued 312,351 shares of the Company’s common stock to the Representative, fully satisfying the Company’s obligations. Also, as a result of the completion of the IPO, the Company issued 85,739 shares of its common stock to a consultant. The value of these shares issued at the IPO price of $5.00 per share was charged to operating expenses in the Company’s financial statements. Preferred Stock On October 28, 2021, the Company entered into an Agreement (the “Exchange Agreement”) with TTAG’s minority shareholder. Pursuant to the Exchange Agreement, TTAG’s minority shareholder agreed to exchange 574,033 shares of Series A Convertible Preferred Stock issued by TTAG, representing its entire ownership interest in TTAG, for the Company’s Series A Preferred Stock, representing a 24% ownership interest in the Company’s fully-diluted capital, which includes the pro forma conversion of all outstanding convertible preferred stock and promissory notes, options, and warrants. Pursuant to the terms of the Exchange Agreement, the Company issued TTAG’s minority shareholder 2,550,763 shares of Series A Preferred Stock. These shares were subject to anti-dilution protection to maintain TTAG’s minority shareholder’s 24% ownership interest in the Company, excluding any shares issued by the Company in an IPO or a qualified offering of at least $5,000 at a per share price of at least $3.3737. Upon conversion of the Company’s convertible notes payable as described in Note 6, the Company issued 1,172,346 shares of its common stock to TTAG’s minority shareholder. In accordance with ASC 810-10-45-23, the Company did not recognize any gain or loss in the consolidated statements of operations and comprehensive loss in conjunction with the Exchange Agreement. The carrying value of the non-controlling interest in TTAG was reduced to zero, and the value of the Company’s investment in TTAG increased accordingly. The shares of Series A Preferred Stock issued were recorded at fair value. The difference between the increase in the Company’s investment and the fair value of the Series A Preferred Stock issued was recorded as a decrease in Additional Paid in Capital (“APIC”). The resulting negative APIC was then reclassified to accumulated deficit. In a series of closings from 2012 through 2015, the Company issued an aggregate of 491,222 shares of Series B Convertible Preferred Stock (“Series B Preferred Stock”) at $2.795 per share for proceeds of $1,272, net of stock issuance costs. The Company classified the convertible preferred stock outside of total stockholders’ deficit because, in the event of certain deemed liquidation events that are not solely within the control of the Company, the shares would become redeemable at the option of the holders. The Company did not adjust the carrying values of the convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable of occurring. Conversion At the option of the holder, shares of Series A and Series B Preferred Stock were convertible into common stock at a conversion rate of one-to-0.5, subject to adjustments for stock dividends, splits, combinations, and similar events. Automatic conversion will occur in the event of a firmly underwritten public offering of common stock of the Company at a price of at least $4.00 per share, subject to appropriate adjustments for stock dividends, splits, combinations, and similar events, and with total gross proceeds to the Company of at least $15,000, before deduction of underwriters’ commissions and expenses. As noted above, the Series A and Series B Preferred Stock were converted to common stock at the time of the Company’s IPO. Redemption The shares of the Series A and Series B Preferred Stock were redeemable only upon acquisition or liquidation of the Company. Liquidation preference With respect to any distributions in connection with a liquidation, dissolution or winding up of the Company, or in connection with the sale of voting control of all or substantially all of the assets of the Company, by way of merger, acquisition, consolidation or similar transaction, prior to any distribution to common stockholders, the holders of Series A and Series B Preferred Stock were entitled to receive $1.526 and $4.981 per share, respectively, plus any declared but unpaid dividends, adjusted to reflect any dividends previously paid. If, upon the occurrence of such event, the assets and funds distributed among the holders of Series A and Series B Preferred Stock shall be insufficient to permit the payment to such holders of the full liquidation preference amounts, the entire assets and funds of the Company legally available shall be distributed ratably among the preferred stockholders in proportion to the preferential amount to which each holder is entitled. After payment of the liquidation preferences, the holders of common stock are entitled to receive the remaining assets of the Company available for distribution to its stockholders pro rata based on the number of shares of common stock held by each holder. Voting rights The holders of vested shares of common stock shall be entitled to vote on any matter submitted to a vote of the stockholders and each such holder shall be entitled to one vote per share of common stock held. The holders of Series A and Series B Preferred Stock were entitled to vote together with the common stock as a single class on any matter submitted to a vote of the stockholders. Holders of Series A and Series B Preferred Stock were entitled to the number of votes equal to the number of common stock issuable upon conversion of their respective Series A and Series B Preferred Stock at the time such shares are voted. The holders of a majority of the preferred stock had additional voting rights as specified in the Company’s Amended and Restated Certificate of Incorporation, as amended. Equity awards In 2012, the Board of Directors of the Company (the “Board”) approved the Tenon Medical, Inc. 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan provides for the issuance of common stock options, appreciation rights, and other awards to employees, directors, and consultants. Options issued under the 2012 Plan generally vest over a period of two On January 10, 2022 and February 2, 2022, the Board and stockholders, respectively, of the Company approved the Tenon Medical, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), which was effective on April 25, 2022. The number of shares of common stock that may be subject to awards and sold under the 2022 Plan is equal to 1,600,000. Automatic annual increases in number of shares available for issuance under the 2022 Plan is equal to the least of (a) 1,100,000 shares, (b) 4% of the total number of shares of all classes of common stock outstanding on the last day of the immediately preceding fiscal year, or (c) such number determined by the 2022 Plan administrator no later than the last day of the immediately preceding fiscal year. Annual increases will continue until the tenth anniversary of the earlier of the Board or stockholder approval of the 2022 Plan, which is January 10, 2032. Upon the effective date of the 2022 Plan, the Board terminated the 2012 Plan such that no new equity awards will be issued by the 2012 Plan. The Company adopted the fair value recognition provisions in accordance with authoritative guidance related to equity-based payments. Compensation expense in 2022 and 2021 includes the portion of awards vested in the periods for all equity-based awards granted, based on the grant date fair value estimated using a Black-Scholes option valuation model, consistent with authoritative guidance. A summary of the Company’s share option and restricted stock unit activity under its plans is as follows: Number of Weighted Number of Weighted-average Grant Outstanding at December 31, 2021 727,394 $ 5.32 — $ — Granted 113,950 $ 2.47 1,318,530 $ 7.93 Forfeited — $ — — $ — Outstanding at September 30, 2022 841,344 $ 4.93 1,318,530 $ 7.93 The following table sets forth stock-based compensation expense recognized for the three and nine months ended September 30, 2022 and 2021: Three months ended Nine months ended 2022 2021 2022 2021 Research and development $ 374 $ 23 $ 581 $ 36 Sales and marketing 37 10 61 18 General, and administrative 623 110 1,113 154 Total stock-based compensation expense $ 1,034 $ 143 $ 1,755 $ 208 At September 30, 2022, there were 167,520 shares available for issuance under the 2022 Plan. Warrants During 2020, the Company issued warrants to purchase 25,000 shares of common stock to a consultant. The warrants, which are equity-classified, are immediately exercisable at an exercise price of $5.20 per share. The fair value of the warrants on the grant date was $2.30 per warrant, which was calculated based on the following weighted-average assumptions, using a Black-Scholes option valuation model: expected term of 5.00 years; expected volatility of 51.88%; dividend yield of 0%, and risk-free interest rate of 0.30%. The Company recorded deferred offering costs of approximately $58 associated with these warrants during 2020 which was recorded in additional paid-in capital in 2022 . In April 2022, as noted above, the Company granted the Underwriters warrants to purchase a total of 96,000 shares of the Company’s common stock. The warrants are immediately exercisable at an exercise price of $5.00 per share and expire on the fifth anniversary of the commencement of sales under the IPO. The fair value of the warrants on the grant date was $2.75 per warrant, which was calculated based on the following weighted-average assumptions, using a Black-Scholes option valuation model: expected term of 5.00 years; expected volatility of 62.55%; dividend yield of 0%, and risk-free interest rate of 2.92%. The Company recorded the fair value of these warrants of approximately $264 as an issuance cost to additional paid-in capital in 2022. As the IPO issuance costs were also recorded to additional paid-in capital, the net impact was $0.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Sales Representative Agreement In April 2020, the Company entered into an Exclusive Sales Representative Agreement, under which the counterparty to the agreement (the “Representative”) received exclusive rights to market, promote, and distribute The Catamaran The amended agreement restructured the calculation of the bonus paid to the Representative upon an acquisition, removed the bonus payable upon an IPO, and allows the Company to terminate the amended agreement as long as the bonus paid to the Representative is at least $6,000. In June 2021, the Company issued a $50 convertible note payable to the Chief Executive Officer of the Representative, as part of the convertible debt offering described in Note 6. In October 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement with the Representative. See Note 12. Litigation In the normal course of business, the Company may possibly be named as a defendant in various lawsuits. On September 2, 2021, Khalid Mentak, a former director and Chief Executive Officer of the Company filed an arbitration claim with the American Arbitration Association (“AAA”) against the Company, asserting damages in excess of $3,000, plus attorneys’ fees and other costs, for alleged unpaid wages, defamation, and other claims. The services provided by Mr. Mentak were governed by a Consulting Agreement between the Company and Key Medical Technologies, Inc (“Key Medical”), a company which Mr. Mentak served as Chief Executive Officer. The AAA proceeding was also initiated pursuant to the arbitration provision in the Consulting Agreement. The parties selected an arbitrator and the Company filed a motion to dismiss the proceeding as currently pled because the proper parties should be Key Medical and the Company, and not Mr. Mentak as an individual. The arbitrator ruled that Mr. Mentak was the real-party-in-interest and denied the motion, without prejudice to any arguments on the merits of the underlying claims. On March 1, 2022, Mr. Mentak filed a more detailed Statement of Claims, which the Company responded to on March 16, 2022. The Company also filed a cross-complaint for declaratory relief seeking to establish its rights and obligations under the Consulting Agreement with respect to the claimant and Key Medical, which was formally named a defendant in the cross complaint. The claimant objected to the cross-complaint as unnecessary. On July 21, 2022, the Company entered into a Settlement Agreement and General Release of All Claims (the “Settlement Agreement”) with Key Medical and Mr. Mentak to settle all claims and counterclaims. Pursuant to the Settlement Agreement, the Company has agreed to pay Key Medical the total sum of $1,200. The settlement amount was fully paid as of September 30, 2022.

Concentrations of Risk

Concentrations of Risk	9 Months Ended
Concentrations of Risk	Sep. 30, 2022
Risks and Uncertainties [Abstract]
Concentrations of Risk	10. Concentrations of Risk Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances at financial institutions located in California and Switzerland. Accounts at the U.S. financial institutions are secured by the Federal Deposit Insurance Corporation. At times, balances may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. The Company grants unsecured credit to its customers based on an evaluation of the customer’s financial condition and a cash deposit is generally not required. Management believes its credit policies do not result in significant adverse risk and historically has not experienced significant credit-related losses. Currency risk The Company’s subsidiary, Tenon Technology AG, realizes a portion of its expenses in Swiss francs. Consequently, certain assets and liabilities are exposed to foreign currency fluctuations. At September 30, 2022 and December 31, 2021, approximately $8 and $21, respectively, of the Company’s net monetary assets were denominated in Swiss francs. The Company has not entered into any hedging transactions to reduce the exposure to currency risk.

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions During 2018 through 2020, the Company’s subsidiary issued convertible promissory notes to TTAG’s minority shareholder. In November 2020, these notes payable and accrued interest were converted into TTAG shares. In June 2021, the Company’s subsidiary issued a convertible promissory note for approximately $107 to TTAG’s minority shareholder. The Company purchased this note and accrued interest of $114 in October 2021 from TTAG’s minority shareholder. See Note 6. The Company had a consulting agreement with a company owned by the former Chief Executive Officer of the Company. Under this consulting agreement, the Chief Executive Officer was to provide services from 2015 through June 1, 2021. Total payments under the consulting agreement of $600 are to be paid as follows: (a) $300 paid upon closing of financing round of at least $5,000, followed by twelve monthly payments of $25 per month; (b) $300 paid upon achieving at least $3,000 of annual revenue and a financing round of less than $5,000; or (c) the entire $600 payable immediately upon an acquisition of the Company. During the three months ended September 30, 2022 and 2021, the Company recorded consulting expense of $0 and $8, respectively, related to this agreement. During the nine months ended September 30, 2022 and 2021, the Company recorded expense of $574 and $25, respectively, related to this agreement. As of September 30, 2022 and December 31, 2021, approximately $0 and $600, respectively, owed to this party was included in accrued expenses with respect of these services. See Note 9. During 2021, the Company issued convertible promissory notes totaling $620 to officers, directors, and their family members. See Note 6. In addition, a note was issued to the Chief Executive Officer of the Representative described in Note 9. On October 28, 2021, the Company entered into an agreement with TTAG’s minority shareholder. See Note 8. Pursuant to the terms of the Exchange Agreement, the Company purchased the convertible note and accrued interest between TTAG and Zuhlke Ventures AG (“ZVAG”), TTAG’s minority shareholder, in the amount of approximately $114. On December 31, 2021, the Company and TTAG entered into the IP Sale and Purchase Agreement, whereby TTAG transferred certain patents and trademarks to the Company. In connection with this transfer, the Company issued an unsecured promissory note to TTAG in the amount of $818 which eliminates in consolidation.

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On October 6, 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement (the “Termination Agreement”) with the Representative, which terminated the Restated Sales Agreement. In accordance with the Termination Agreement, (i) the Company paid the Representative $1,000 in cash; and (ii) the Company agreed to pay the Representative (a) $85 per month during the six months after the date of the Termination Agreement in return for efforts by the Representative to transition operations to the Company, (b) 20% of net sales of the Product sold in the United States and Puerto Rico until December 31, 2023 and (c) after December 31, 2023, a commission in an amount equal to 10% of net sales until such time as the aggregate amount paid to the Representative under this clause (c) and clause (b) above equal $3,600. In the event of an acquisition of the Company, the Company will pay the Representative $3,600 less previous amounts paid pursuant to clause (b) and clause (c) above In connection with the above terms, the Company will record a charge of $4,600 to sales and marketing expenses in the fourth quarter of 2022. Simultaneously with the execution of the Termination Agreement, the Company entered into a Consulting Agreement dated October 6, 2022, with the Representative (the “Consulting Agreement”). Under the terms and conditions of the Consulting Agreement, the Representative is tasked with organizing, recruiting, training, and coordinating the Company’s Clinical Specialist program, Physician Education program and Sales Education program as more specifically described in the Consulting Agreement. The term of the Consulting Agreement is from October 6, 2022, until October 05, 2023, unless extended by mutual agreement of the parties in writing for additional one-year terms, or terminated in accordance with the terms of the Consulting Agreement. In consideration for the services to be provided, the Company shall pay the Representative a base consulting fee of $700 per year, payable in monthly instalments, along with additional compensation of $62.5 per quarter, if certain sales targets are met, for four quarters; along with any travel and related out-of-pocket expenses incurred by the Representative in connection with the performance of the services.

Summary of Significant Accoun_2

Summary of Significant Accounting Principles (Policies)	9 Months Ended
Summary of Significant Accounting Principles (Policies)	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation We have prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the SEC. As permitted under these rules and regulations, we have condensed or omitted certain financial information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These condensed consolidated financial statements have been prepared on the same basis as our annual consolidated financial statements and, in management’s opinion, reflect all adjustments consisting only of normal recurring adjustments that are necessary for a fair presentation of our financial information. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. The financial statements of the subsidiary are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects. The amount of consolidated net loss attributable to the Company and ownership interests in TTAG held by parties other than the Company are both presented on the face of the Consolidated Statements of Operations. As TTAG is a wholly-owned subsidiary as of September 30, 2022, this separate presentation has been discontinued for the three and nine months then ended. Further, as the Company purchased the non-controlling interest in TTAG as of October 28, 2021, the amount of consolidated net loss attributable to the Company and the non-controlling interest are both presented on the face of the Consolidated Statements of Operations and Comprehensive Loss. These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in our amended Registration Statement. The Company’s significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in our amended Registration Statement. There have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2022.
Going concern uncertainty and liquidity requirements	Going concern uncertainty and liquidity requirements The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and starts the commercial launch of The Catamaran System. On April 29, 2022, the Company closed an initial public offering (the “IPO”) of its common stock for proceeds of $13,765, net of issuance costs. Based on the Company’s current level of revenues and expenditures, the Company believes that its existing cash and cash equivalents and short-term investments as of September 30, 2022 will
Use of estimates	Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, obsolescence of inventory, stock-based compensation and the fair value of the Company’s common stock and preferred stock.
Income Taxes	Income Taxes The Company accounts for income taxes utilizing ASC 740, “Income Taxes”. ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company’s financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
Impact of COVID-19	Impact of COVID-19 In March 2020, the World Health Organization declared the coronavirus (“COVID-19”) outbreak to be a pandemic. During the years ended December 31, 2021 and 2020 and the nine months ended September 30, 2022, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these consolidated financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it.
Net loss per share	Net loss per share Basic net loss per share is based upon the weighted-average number of common shares outstanding. Diluted net loss per share is based on the assumption that all potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. The Company’s weighted-average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive. The Company had the following dilutive common stock equivalents as of September 30, 2022 and 2021 which were excluded from the calculation because their effect was anti-dilutive. September 30, September 30, Outstanding restricted stock units 1,318,530 — Outstanding stock options 841,344 705,394 Outstanding warrants 121,000 25,000 Common shares convertible from notes payable — 2,079,510 Common shares convertible from preferred stock — 245,611 Total 2,280,874 3,055,515
Recent Accounting Pronouncements	Recent Accounting Pronouncements There have been no accounting pronouncements or changes in accounting pronouncements in the nine months ended September 30, 2022 that are significant or potentially significant to the Company.

Summary of Significant Accoun_3

Summary of Significant Accounting Principles (Tables)	9 Months Ended
Summary of Significant Accounting Principles (Tables)	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Securities Excluded Due To Anti Dilutive Effect	The Company had the following dilutive common stock equivalents as of September 30, 2022 and 2021 which were excluded from the calculation because their effect was anti-dilutive. September 30, September 30, Outstanding restricted stock units 1,318,530 — Outstanding stock options 841,344 705,394 Outstanding warrants 121,000 25,000 Common shares convertible from notes payable — 2,079,510 Common shares convertible from preferred stock — 245,611 Total 2,280,874 3,055,515

Investments (Tables)

Investments (Tables)	9 Months Ended
Investments (Tables)	Sep. 30, 2022
Investments [Abstract]
Schedule of Investments At Fair Value in Fair Value Hierarchy Level	The following table sets forth by level, within the fair value hierarchy, the Company’s investments at fair value as of September 30, 2022 and December 31, 2021: Level 2 Corporate debt securities: September 30, 2022 $ 9,381 December 31, 2021 $ 4,404
Schedule of Cost And Fair Value of Available For Sale Investments	Cost and fair value of available-for-sale investments as of September 30, 2022 and December 31, 2021 are as follows: Amortized Gross Gross Fair Corporate debt securities: September 30, 2022 $ 9,418 $ — $ (37 ) $ 9,381 December 31, 2021 $ 4,404 $ — $ — $ 4,404

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
Fixed Assets (Tables)	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Summary of Fixed Assets	Fixed assets, net, consisted of the following: September 30, 2022 December 31,2021 Catamaran Tray Sets $ 270 $ 77 IT Equipment 56 17 Lab Equipment 14 — Office Furniture 9 9 Fixed assets, gross 349 103 Less: accumulated depreciation (55 ) (2 ) Fixed assets, net $ 294 $ 101

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
Accrued Expenses (Tables)	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: September 30, December 31, Accrued compensation $ 339 $ 846 Accrued commissions 49 14 Other accrued expenses 215 228 Total accrued expenses $ 603 $ 1,088

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Sep. 30, 2022
Leases [Abstract]
Summary of Supplemental Balance Sheet Information Related To Leases	Supplemental balance sheet information related to leases was as follows: September 30, December 31, 2022 2021 Operating lease right-of-use assets $ 927 $ 1,084 Operating lease liability, current $ (241 ) $ (202 ) Operating lease liability, noncurrent (724 ) (911 ) Total operating lease liabilities $ (965 ) $ (1,113 )
Summary of Future Maturities of Operating Lease Liabilities	Future maturities of operating lease liabilities as of September 30, 2022 were as follows: 2022 $ 73 2023 293 2024 301 2025 310 2026 144 Total lease payments 1,121 Less: imputed interest (156 ) Present value of operating lease liabilities $ 965 Other information: Cash paid for operating leases for the nine months ended September 30, 2022 $ 212 Cash paid for operating leases for the nine months ended September 30, 2021 $ 58 Remaining lease term - operating leases (in years) 3.75 Average discount rate - operating leases 8.0 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Sep. 30, 2022
Equity [Abstract]
Summary of Share Based Compensation Arrangements By Share Based Payment Award	A summary of the Company’s share option and restricted stock unit activity under its plans is as follows: Number of Weighted Number of Weighted-average Grant Outstanding at December 31, 2021 727,394 $ 5.32 — $ — Granted 113,950 $ 2.47 1,318,530 $ 7.93 Forfeited — $ — — $ — Outstanding at September 30, 2022 841,344 $ 4.93 1,318,530 $ 7.93
Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs	The following table sets forth stock-based compensation expense recognized for the three and nine months ended September 30, 2022 and 2021: Three months ended Nine months ended 2022 2021 2022 2021 Research and development $ 374 $ 23 $ 581 $ 36 Sales and marketing 37 10 61 18 General, and administrative 623 110 1,113 154 Total stock-based compensation expense $ 1,034 $ 143 $ 1,755 $ 208

Summary of Significant Accoun_4

Summary of Significant Accounting Principles - Schedule of Securities Excluded Due To Anti Dilutive Effect (Detail) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,280,874	3,055,515
Outstanding restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,318,530	0
Outstanding stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	841,344	705,394
Outstanding warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	121,000	25,000
Common shares convertible from notes payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	2,079,510
Common shares convertible from preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	245,611

Summary of Significant Accoun_5

Summary of Significant Accounting Principles - Additional Information (Detail) - USD ($) $ in Thousands		9 Months Ended
	Apr. 29, 2022	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Percentage of valuation allowance in deferred tax assets		100%
Proceeds from Issuance of Common Stock	$ 13,765	$ 14,139	$ 0

Investments - Schedule of Inves

Investments - Schedule of Investments At Fair Value in Fair Value Hierarchy Level (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	$ 9,381	$ 4,404

Investments - Schedule of Cost

Investments - Schedule of Cost And Fair Value of Available For Sale Investments (Detail) - Corporate Debt Securities [Member] - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 9,418	$ 4,404
Unrealized ‎Gains	0	0
Unrealized Losses	(37)	0
Fair Value	$ 9,381	$ 4,404

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Other than temporary impairment losses	$ 10	$ 0	$ 37	$ 0
Net gain on investments	72	$ 1	108	$ 1
Prepaid Expenses and Other Current Assets [Member]
Accrued interest	$ 6		$ 6		$ 18

Fixed Assets - Summary of Fixed

Fixed Assets - Summary of Fixed Assets and Equipment Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fixed Assets [Line Items]
Fixed Assets, gross	$ 349	$ 103
Less: accumulated depreciation	(55)	(2)
Fixed Assets, net	294	101
Catamaran Tray Sets [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	270	77
IT Equipment [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	56	17
Lab Equipment [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	14	0
Office Equipment [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	$ 9	$ 9

Fixed Assets - Additional Infor

Fixed Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 24	$ 1	$ 53	$ 1

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued compensation	$ 339	$ 846
Accrued commissions	49	14
Other accrued expenses	215	228
Total accrued expenses	$ 603	$ 1,088

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands									1 Months Ended	12 Months Ended
	Apr. 29, 2022	May 31, 2021	Apr. 30, 2021	Jan. 31, 2021	Nov. 30, 2020	Oct. 31, 2019	Jun. 30, 2019	Dec. 31, 2016	May 31, 2021	Dec. 31, 2021	Sep. 30, 2022	Oct. 28, 2021	Jul. 31, 2021	Jun. 30, 2021	Dec. 31, 2015
IPO [Member]
Debt Disclosure [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	3,955,415
Convertible Promissory Notes [Member]
Debt Disclosure [Line Items]
Proceeds from related party debt										$ 620
Convertible Promissory Notes [Member] \| Consultant [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount		$ 68					$ 68		$ 68						$ 53
Interest rate		8%					8%		8%						8%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing							90%								90%
Maturity date		May 07, 2022					Jun. 12, 2021
Debt Conversion Convertible Automatically Upon The Minimum Amount Of Initial Public Offering Or Capital Stock Financing		$ 5,000							$ 5,000
Debt Instrument Conversion Price Equal To Percentage Of IPO Price		80%							80%
Debt instrument conversion price per share		$ 1.9565							$ 1.9565
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument		$ 5,000							$ 5,000
Accrued Interest										14	$ 0
Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt							$ 1,000								$ 500
Convertible Promissory Notes [Member] \| Entity Minority Shareholder [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount														$ 107
Interest rate														8%
Debt instrument convertible note and accrued interest												$ 114
Convertible Promissory Notes [Member] \| Vendor [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount			$ 118					$ 118
Interest rate			8%					8%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing								90%
Maturity date			Apr. 30, 2022					Jan. 01, 2019
Debt Instrument Conversion Price Equal To Percentage Of IPO Price			80%
Debt instrument conversion price per share			$ 1.9565
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument			$ 5,000
Accrued Interest										56	0
Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt			500
Convertible Promissory Notes [Member] \| Chief Executive Officer [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount			$ 70			$ 70
Interest rate			8%			8%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing						80%
Maturity date			Apr. 30, 2022			Oct. 12, 2022
Debt Instrument Conversion Price Equal To Percentage Of IPO Price			70%
Debt instrument conversion price per share			$ 1.9565
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument			$ 5,000
Accrued Interest										12	0
Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt			500
Convertible Promissory Notes [Member] \| Investor [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount		$ 50				$ 50			$ 50
Interest rate		8%				8%			8%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing						80%
Maturity date		May 03, 2022				Oct. 21, 2022
Debt Instrument Conversion Price Equal To Percentage Of IPO Price		70%							70%
Debt instrument conversion price per share		$ 1.9565							$ 1.9565
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument		$ 5,000							$ 5,000
Accrued Interest										9	0
Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt		500							500
Convertible Promissory Notes [Member] \| Investor One [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount		$ 200			$ 200				$ 200
Interest rate		8%			8%				8%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing					80%
Maturity date		May 03, 2022			Nov. 16, 2022
Debt Instrument Conversion Price Equal To Percentage Of IPO Price		70%							70%
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument		$ 5,000							$ 5,000
Accrued Interest										18	0
Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt					$ 2,000
Convertible Promissory Notes [Member] \| Officers, Directors, and their Family [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount													$ 620
Interest rate													8%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing													70%
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument													$ 5,000
Accrued Interest										527	0
Proceeds from related party debt									$ 12,177
Valuation amount													22,500
Debt issuance costs													71
Convertible Promissory Notes [Member] \| Chief Executive Officer of the Representative [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount													$ 50
Promissory Notes [Member] \| Law Firm [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount				$ 131
Interest rate				3%
Maturity date				Jul. 27, 2021
Percentage Of Increase IN Interest Rate If Principal And Interest Not Been Paid By Maturity Date				5%
Convertible Promissory Notes One [Member] \| Vendor [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount			40
Convertible Promissory Notes Two [Member] \| Vendor [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount			$ 170
Convertible Promissory Notes One and Two [Member] \| Vendor [Member]
Debt Disclosure [Line Items]
Interest rate			8%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing			70%
Debt Instrument Conversion Price Equal To Percentage Of IPO Price			70%
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument			$ 5,000
Accrued Interest										$ 11	$ 0

Leases - Summary of Supplementa

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Lessee Disclosure [Abstract]
Operating lease right-of-use assets	$ 927	$ 1,084
Operating lease liability, current	(241)	(202)
Operating lease liability, noncurrent	(724)	(911)
Total operating lease liabilities	$ (965)	$ (1,113)

Leases - Summary of Future Matu

Leases - Summary of Future Maturities of Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Lessee Disclosure [Abstract]
2022	$ 73
2023	293
2024	301
2025	310
2026	144
Total lease payments	1,121
Less: imputed interest	(156)
Present value of operating lease liabilities	965		$ 1,113
Cash paid for operating leases	$ 212	$ 58
Remaining lease term - operating leases (in years)	3 years 9 months
Average discount rate - operating leases	8%

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Lessee, Operating lease, Expiration, Month and Year	2026-06
General and Administrative Expense [Member]
Operating lease costs		$ 73	$ 73	$ 219	$ 85

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands			1 Months Ended			9 Months Ended		12 Months Ended	48 Months Ended
	Apr. 29, 2022 USD ($) $ / shares shares	Oct. 28, 2021 USD ($) $ / shares shares	Apr. 30, 2022 USD ($) yr $ / shares shares	Oct. 31, 2021 shares	May 31, 2021 shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 shares	Dec. 31, 2020 USD ($) yr $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Apr. 26, 2022 $ / shares shares	Apr. 25, 2022 shares	Feb. 28, 2022 shares	Dec. 31, 2021 $ / shares shares	Aug. 31, 2021 shares	Jul. 31, 2021 shares	Apr. 30, 2021 shares	Feb. 18, 2014 $ / shares shares
Common stock, Shares authorized				10,487,904		130,000,000						130,000,000	10,487,904			7,000,000	3,937,550
Common stock, Par or stated value per share \| $ / shares						$ 0.001							$ 0.001				$ 0.001
Common stock, Voting rights						one vote
Stock issued during period, shares, issued for services to consultant	85,739
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs \| $			$ 0
Representative [Member] \| Other [Member]
Ownership Percentage	3%
IPO [Member]
Common stock, Par or stated value per share \| $ / shares										$ 0.001
Common stock shares subscribed but unissued										3,200,000
Sale of stock, price per share \| $ / shares	$ 5									$ 5
Net proceeds from the IPO after deducting expenses \| $	$ 13,800
Common Stock Warrants [Member] \| Consultant [Member]
Class of warrant or right, number of common stock called by warrants or rights			96,000					25,000
Class of warrants or rights exercise price \| $ / shares			$ 5					$ 5.2
Class of warrants of rights grant date fair value of warrants \| $ / shares			$ 2.75					$ 2.3
Deferred costs associated with warrants \| $			$ 264					$ 58
Common Stock Warrants [Member] \| Consultant [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input \| yr			5					5
Common Stock Warrants [Member] \| Consultant [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input			62.55					51.88
Common Stock Warrants [Member] \| Consultant [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0					0
Common Stock Warrants [Member] \| Consultant [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input			2.92					0.3
Conversion of Convertible Notes to Common Stock [Member]
Number of shares issued during the period on conversion of convertible notes	3,955,415
Conversion of Series A and Series B Preferred Stock to Common Stock [Member]
Conversion of stock, Shares issued	2,693,342
Two Thousand And Twelve Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance															737,516	662,516
Two Thousand and Twenty Two Equity Incentive Plan [Member]
Share based compensation by share based payment award number of shares available for grant											1,600,000
Share based compensation arrangement by share based payment award cumulative annual increase shares											1,100,000
Share based compensation arrangement by share based payment award cumulative annual increase percentage											4%
Employee Stock Option [Member] \| Two Thousand And Twelve Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
Minimum [Member] \| Two Thousand And Twelve Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance														737,516
Minimum [Member] \| Employee Stock Option [Member] \| Two Thousand And Twelve Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						2 years
Maximum [Member] \| Two Thousand And Twelve Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance														799,266
Maximum [Member] \| Employee Stock Option [Member] \| Two Thousand And Twelve Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						4 years
Common Stock [Member]
Stock issued during period, Shares, New issues						3,200,000
Stock issued during period, shares, issued for services to consultant						398,090	115,507
Common Stock [Member] \| Event Triggering Automatic Conversion [Member]
Minimum price per share at which shares are issued under firmly underwritten public offering \| $ / shares						$ 4
Minimum gross proceeds from firmly underwritten public offering \| $						$ 15,000
Noncontrolling Interest [Member] \| Conversion of Series A and Series B Preferred Stock to Common Stock [Member]
Conversion of stock, Shares issued	1,172,346	1,172,346
TTAG [Member]
Carrying value of the non controlling interest \| $						0
Shares Subject To Anti Dilution Protection [Member]
Minimum threshold amount of shares issued in an initial public offering or a qualified offering that were excluded \| $		$ 5,000
Minimum threshold price per share of shares issued in an initial public offering or a qualified offering that were excluded \| $ / shares		$ 3.3737
Shares Subject To Anti Dilution Protection [Member] \| Other [Member]
Ownership Percentage		24%
Exchange Agreement [Member]
Gain loss on agreement \| $						$ 0
Underwriting Agreement [Member]
Class of warrant or right, number of common stock called by warrants or rights										96,000
Class of warrants or rights exercise price \| $ / shares										$ 5
Amended and Restated Exclusive Sales Representative Agreement [Member] \| Representative [Member]
Stock issued during period, Shares, New issues	312,351			44,447	53,757
Amended and Restated Exclusive Sales Representative Agreement [Member] \| Representative [Member] \| Other [Member]
Ownership Percentage					3%
Convertible Preferred Stock [Member]
Temporary equity, Shares authorized				3,297,061								20,000,000				2,460,802	2,099,525
Series A Convertible Preferred Stock [Member]
Temporary equity, Shares authorized						4,500,000							2,805,839			1,798,905
Temporary equity, Liquidation preference per share \| $ / shares						$ 1.526
Series A Convertible Preferred Stock [Member] \| Exchange Agreement [Member] \| Shares Converted By TTAG s Minority Shareholder For Company Shares [Member]
Conversion of stock, Shares converted		574,033
Conversion of stock, Shares issued		2,550,763
Series A Convertible Preferred Stock [Member] \| Exchange Agreement [Member] \| Shares Converted By TTAG s Minority Shareholder For Company Shares [Member] \| Other [Member]
Ownership Percentage		24%
Series B Convertible Preferred Stock [Member]
Temporary equity, Shares authorized						491,222							491,222
Stock issued during period, Shares, New issues									491,222
Shares issued, Price per share \| $ / shares									$ 2.795
Proceeds from issuance of convertible preferred stock \| $									$ 1,272
Temporary equity, Liquidation preference per share \| $ / shares						$ 4.981
Series A Series B Convertible Preferred Stock [Member]
Conversion ratio						0.5

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Share Based Compensation Arrangements By Share Based Payment Award (Detail)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Number of Shares Subject to Outstanding Stock Options (Beginning Balance) \| shares	727,394
Number of Shares Subject to Outstanding Stock Options Granted \| shares	113,950
Number of Shares Subject to Outstanding Stock Options Forfeited \| shares	0
Number of Shares Subject to Outstanding Stock Options Outstanding (Ending Balance) \| shares	841,344
Weighted Average Exercise Price Per Share Outstanding (Beginning Balance) \| $ / shares	$ 5.32
Weighted Average Exercise Price Per Share Granted \| $ / shares	2.47
Weighted Average Exercise Price Per Share Forfeited \| $ / shares	0
Weighted Average Exercise Price Per Share Outstanding (Ending Balance) \| $ / shares	$ 4.93
Restricted Stock Units (RSUs) [Member]
Number of Outstanding Restricted Stock Units (Beginning Balance) \| shares	0
Number of Outstanding Restricted Stock Units Granted \| shares	1,318,530
Number of Outstanding Restricted Stock Units Forfeited \| shares	0
Number of Outstanding Restricted Stock Units (Ending Balance) \| shares	1,318,530
Share-based Payment Arrangement, Option [Member]
Weighted-average Grant Date Fair Value per Share (Beginning Balance) \| $ / shares	$ 0
Weighted-average Grant Date Fair Value per Share Granted \| $ / shares	7.93
Weighted-average Grant Date Fair Value per Share Forfeited \| $ / shares	0
Weighted-average Grant Date Fair Value per Share (Ending Balance) \| $ / shares	$ 7.93

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	$ 1,034	$ 143	$ 1,755	$ 208
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	374	23	581	36
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	37	10	61	18
General, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	$ 623	$ 110	$ 1,113	$ 154

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands				1 Months Ended			3 Months Ended		9 Months Ended
	Jul. 21, 2022	Apr. 29, 2022	Sep. 02, 2021	Oct. 31, 2021	May 31, 2021	Apr. 30, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021
Other Commitments [Line Items]
Sales and marketing expense							$ 645	$ 556	$ 2,864	$ 1,473
Stock issued during period value new issues									$ 13,765
Key Medical [Member]
Other Commitments [Line Items]
Litigation Settlement	$ 1,200
Representative [Member] \| Other [Member]
Other Commitments [Line Items]
Ownership Percentage		3%
Representative [Member] \| Convertible Notes Payable [Member]
Other Commitments [Line Items]
Debt instrument principal amount											$ 50
Khalid Mentak [Member] \| Arbitration Claim [Member]
Other Commitments [Line Items]
Loss Contingency, Damages Sought, Value			$ 3,000
Sales Representative Agreement [Member]
Other Commitments [Line Items]
Agreement term						5 years
Agreement additional extension term						5 years
Amended and Restated Exclusive Sales Representative Agreement [Member] \| Representative [Member]
Other Commitments [Line Items]
Payment of representative bonus					$ 500
Stock issued during period shares new issues		312,351		44,447	53,757
Sales and marketing expense					$ 880
Stock issued during period value new issues				$ 333
Minimum representative bonus payable				$ 6,000
Amended and Restated Exclusive Sales Representative Agreement [Member] \| Representative [Member] \| Other [Member]
Other Commitments [Line Items]
Ownership Percentage					3%

Concentrations of Risk - Additi

Concentrations of Risk - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Switzerland, Francs [Member] \| Net Assets, Geographic Area [Member]
Concentration Risk [Line Items]
Net assets	$ 8	$ 21

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 01, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Oct. 28, 2021	Jun. 30, 2021
Related Party Transaction [Line Items]
Revenues		$ 208	$ 70	$ 414	$ 107
Convertible Promissory Notes [Member]
Related Party Transaction [Line Items]
Proceeds from related party debt						$ 620
IP Sale and Purchase Agreement [Member] \| Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Debt instrument principal amount						818
Entity Minority Shareholder [Member] \| Convertible Promissory Notes [Member]
Related Party Transaction [Line Items]
Debt instrument principal amount								$ 107
Debt instrument convertible note and accrued interest							$ 114
Former Chief Executive Officer [Member] \| Consulting Agreement [Member]
Related Party Transaction [Line Items]
Related party transaction amounts of payments	$ 600
Related party transaction, expenses from transactions with related party		0	$ 8	574	$ 25
Due to Related Parties		$ 0		$ 0		$ 600
Former Chief Executive Officer [Member] \| Consulting Agreement Tranche One [Member]
Related Party Transaction [Line Items]
Related party transaction amounts of payments	300
Minimum threshold financing	5,000
Consulting agreement monthly payments	25
Former Chief Executive Officer [Member] \| Consulting Agreement Tranche Two [Member]
Related Party Transaction [Line Items]
Related party transaction amounts of payments	300
Minimum threshold financing	5,000
Revenues	$ 3,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)		3 Months Ended			9 Months Ended
	Oct. 06, 2022	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Subsequent Event [Line Items]
Selling and marketing expense			$ 645,000	$ 556,000	$ 2,864,000	$ 1,473,000
Subsequent Event [Member] \| Termination Agreement [Member] \| Representative [Member]
Subsequent Event [Line Items]
Payment to representative as per agreement	$ 1,000,000
As per agreement value agreed to pay the representative per month	$ 85,000
Percentage of net sales of the product sold agreed to pay the representative	20%
Percentage of commission to net sales agreed to pay the representative until aggregate amount paid	10%
Value of commission agreed to pay as per agreement	$ 3,600,000
As per agreement value to pay the representative in the event of acquisition net of previous amount paid	$ 3,600,000
Selling and marketing expense		$ 4,600,000
Subsequent Event [Member] \| Consulting Agreement [Member]
Subsequent Event [Line Items]
Term of agreement	October 6, 2022, until October 05, 2023
Additional term of agreement by mutual agreement of the parties in writing	1 year
Subsequent Event [Member] \| Consulting Agreement [Member] \| Representative [Member]
Subsequent Event [Line Items]
Consulting fee per year payable in monthly installments	$ 700,000
Additional compensation payable per quarter	$ 62,500